196 related articles for article (PubMed ID: 38592711)
21. Practical Implications of Factor IX Gene Transfer for Individuals with Hemophilia B: A Clinical Perspective.
Miesbach W; Sawyer EK
Hum Gene Ther Clin Dev; 2018 Jun; 29(2):80-89. PubMed ID: 29624465
[TBL] [Abstract][Full Text] [Related]
22. Employing a gain-of-function factor IX variant R338L to advance the efficacy and safety of hemophilia B human gene therapy: preclinical evaluation supporting an ongoing adeno-associated virus clinical trial.
Monahan PE; Sun J; Gui T; Hu G; Hannah WB; Wichlan DG; Wu Z; Grieger JC; Li C; Suwanmanee T; Stafford DW; Booth CJ; Samulski JJ; Kafri T; McPhee SW; Samulski RJ
Hum Gene Ther; 2015 Feb; 26(2):69-81. PubMed ID: 25419787
[TBL] [Abstract][Full Text] [Related]
23. BAX 335 hemophilia B gene therapy clinical trial results: potential impact of CpG sequences on gene expression.
Konkle BA; Walsh CE; Escobar MA; Josephson NC; Young G; von Drygalski A; McPhee SWJ; Samulski RJ; Bilic I; de la Rosa M; Reipert BM; Rottensteiner H; Scheiflinger F; Chapin JC; Ewenstein B; Monahan PE
Blood; 2021 Feb; 137(6):763-774. PubMed ID: 33067633
[TBL] [Abstract][Full Text] [Related]
24. Theodore E. Woodward Award. AAV-mediated gene transfer for hemophilia.
High KA
Trans Am Clin Climatol Assoc; 2003; 114():337-51; discussion 351-2. PubMed ID: 12813929
[TBL] [Abstract][Full Text] [Related]
25. Valoctocogene Roxaparvovec and Etranacogene Dezaparavovec: Novel Gene Therapies for Hemophilia A and B.
Dougherty JA; Dougherty KM
Ann Pharmacother; 2023 Nov; ():10600280231202247. PubMed ID: 37978816
[TBL] [Abstract][Full Text] [Related]
26. Adenovirus-associated virus vector-mediated gene transfer in hemophilia B.
Nathwani AC; Tuddenham EG; Rangarajan S; Rosales C; McIntosh J; Linch DC; Chowdary P; Riddell A; Pie AJ; Harrington C; O'Beirne J; Smith K; Pasi J; Glader B; Rustagi P; Ng CY; Kay MA; Zhou J; Spence Y; Morton CL; Allay J; Coleman J; Sleep S; Cunningham JM; Srivastava D; Basner-Tschakarjan E; Mingozzi F; High KA; Gray JT; Reiss UM; Nienhuis AW; Davidoff AM
N Engl J Med; 2011 Dec; 365(25):2357-65. PubMed ID: 22149959
[TBL] [Abstract][Full Text] [Related]
27. Long-term safety and efficacy of factor IX gene therapy in hemophilia B.
Nathwani AC; Reiss UM; Tuddenham EG; Rosales C; Chowdary P; McIntosh J; Della Peruta M; Lheriteau E; Patel N; Raj D; Riddell A; Pie J; Rangarajan S; Bevan D; Recht M; Shen YM; Halka KG; Basner-Tschakarjan E; Mingozzi F; High KA; Allay J; Kay MA; Ng CY; Zhou J; Cancio M; Morton CL; Gray JT; Srivastava D; Nienhuis AW; Davidoff AM
N Engl J Med; 2014 Nov; 371(21):1994-2004. PubMed ID: 25409372
[TBL] [Abstract][Full Text] [Related]
28. Safety and activity of an engineered, liver-tropic adeno-associated virus vector expressing a hyperactive Padua factor IX administered with prophylactic glucocorticoids in patients with haemophilia B: a single-centre, single-arm, phase 1, pilot trial.
Xue F; Li H; Wu X; Liu W; Zhang F; Tang D; Chen Y; Wang W; Chi Y; Zheng J; Du Z; Jiang W; Zhong C; Wei J; Zhu P; Fu R; Liu X; Chen L; Pei X; Sun J; Cheng T; Yang R; Xiao X; Zhang L
Lancet Haematol; 2022 Jul; 9(7):e504-e513. PubMed ID: 35598604
[TBL] [Abstract][Full Text] [Related]
29. Advances in Gene Therapy for Hemophilia.
Nathwani AC; Davidoff AM; Tuddenham EGD
Hum Gene Ther; 2017 Nov; 28(11):1004-1012. PubMed ID: 28835123
[TBL] [Abstract][Full Text] [Related]
30. Liver Gene Therapy.
Nathwani AC; McIntosh J; Sheridan R
Hum Gene Ther; 2022 Sep; 33(17-18):879-888. PubMed ID: 36082993
[TBL] [Abstract][Full Text] [Related]
31. What´s new in Gene Therapy of Hemophilia.
Rodriguez-Merchan EC
Curr Gene Ther; 2018; 18(2):107-114. PubMed ID: 29446741
[TBL] [Abstract][Full Text] [Related]
32. Adeno-Associated Virus Gene Therapy for Hemophilia.
Samelson-Jones BJ; George LA
Annu Rev Med; 2023 Jan; 74():231-247. PubMed ID: 36103998
[TBL] [Abstract][Full Text] [Related]
33. Hemophilia gene therapy: first, do no harm.
Valentino LA; Kaczmarek R; Pierce GF; Noone D; O'Mahony B; Page D; Rotellini D; Skinner MW
J Thromb Haemost; 2023 Sep; 21(9):2354-2361. PubMed ID: 37353081
[TBL] [Abstract][Full Text] [Related]
34. Optimized human factor IX expression cassettes for hepatic-directed gene therapy of hemophilia B.
Zhang R; Wang Q; Zhang L; Chen S
Front Med; 2015 Mar; 9(1):90-9. PubMed ID: 25663062
[TBL] [Abstract][Full Text] [Related]
35. Dexamethasone Transiently Enhances Transgene Expression in the Liver When Administered at Late-Phase Post Long-Term Adeno-Associated Virus Transduction.
Chai Z; Zhang X; Dobbins AL; Samulski RJ; Merricks EP; Nichols TC; Li C
Hum Gene Ther; 2022 Feb; 33(3-4):119-130. PubMed ID: 34617445
[TBL] [Abstract][Full Text] [Related]
36. The gene therapy journey for hemophilia: are we there yet?
High KA
Blood; 2012 Nov; 120(23):4482-7. PubMed ID: 22829631
[TBL] [Abstract][Full Text] [Related]
37. Gene therapy for hemophilia B using CB 2679d-GT: a novel factor IX variant with higher potency than factor IX Padua.
Nair N; De Wolf D; Nguyen PA; Pham QH; Samara-Kuko E; Landau J; Blouse GE; Chuah MK; VandenDriessche T
Blood; 2021 May; 137(21):2902-2906. PubMed ID: 33735915
[TBL] [Abstract][Full Text] [Related]
38. Advances and challenges for hemophilia gene therapy.
Batty P; Lillicrap D
Hum Mol Genet; 2019 Oct; 28(R1):R95-R101. PubMed ID: 31332444
[TBL] [Abstract][Full Text] [Related]
39. Viral vector-mediated gene therapy for hemophilia.
VandenDriessche T; Collen D; Chuah MK
Curr Gene Ther; 2001 Sep; 1(3):301-15. PubMed ID: 12109144
[TBL] [Abstract][Full Text] [Related]
40. AAV liver expression of FIX-Padua prevents and eradicates FIX inhibitor without increasing thrombogenicity in hemophilia B dogs and mice.
Crudele JM; Finn JD; Siner JI; Martin NB; Niemeyer GP; Zhou S; Mingozzi F; Lothrop CD; Arruda VR
Blood; 2015 Mar; 125(10):1553-61. PubMed ID: 25568350
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
